Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
5 participants in 3 patient groups
Loading...
Central trial contact
Salvatore Marengoni Galdy, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal